TY - JOUR
T1 - Recent Advances in the Lipid Nanoparticle-Mediated Delivery of mRNA Vaccines
AU - Swetha, K.
AU - Kotla, Niranjan G.
AU - Tunki, Lakshmi
AU - Jayaraj, Arya
AU - Bhargava, Suresh K.
AU - Hu, Haitao
AU - Bonam, Srinivasa Reddy
AU - Kurapati, Rajendra
N1 - Publisher Copyright:
© 2023 by the authors.
PY - 2023/3
Y1 - 2023/3
N2 - Lipid nanoparticles (LNPs) have recently emerged as one of the most advanced technologies for the highly efficient in vivo delivery of exogenous mRNA, particularly for COVID-19 vaccine delivery. LNPs comprise four different lipids: ionizable lipids, helper or neutral lipids, cholesterol, and lipids attached to polyethylene glycol (PEG). In this review, we present recent the advances and insights for the design of LNPs, as well as their composition and properties, with a subsequent discussion on the development of COVID-19 vaccines. In particular, as ionizable lipids are the most critical drivers for complexing the mRNA and in vivo delivery, the role of ionizable lipids in mRNA vaccines is discussed in detail. Furthermore, the use of LNPs as effective delivery vehicles for vaccination, genome editing, and protein replacement therapy is explained. Finally, expert opinion on LNPs for mRNA vaccines is discussed, which may address future challenges in developing mRNA vaccines using highly efficient LNPs based on a novel set of ionizable lipids. Developing highly efficient mRNA delivery systems for vaccines with improved safety against some severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants remains difficult.
AB - Lipid nanoparticles (LNPs) have recently emerged as one of the most advanced technologies for the highly efficient in vivo delivery of exogenous mRNA, particularly for COVID-19 vaccine delivery. LNPs comprise four different lipids: ionizable lipids, helper or neutral lipids, cholesterol, and lipids attached to polyethylene glycol (PEG). In this review, we present recent the advances and insights for the design of LNPs, as well as their composition and properties, with a subsequent discussion on the development of COVID-19 vaccines. In particular, as ionizable lipids are the most critical drivers for complexing the mRNA and in vivo delivery, the role of ionizable lipids in mRNA vaccines is discussed in detail. Furthermore, the use of LNPs as effective delivery vehicles for vaccination, genome editing, and protein replacement therapy is explained. Finally, expert opinion on LNPs for mRNA vaccines is discussed, which may address future challenges in developing mRNA vaccines using highly efficient LNPs based on a novel set of ionizable lipids. Developing highly efficient mRNA delivery systems for vaccines with improved safety against some severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants remains difficult.
KW - COVID-19
KW - lipid nanoparticles
KW - mRNA
KW - vaccine
UR - http://www.scopus.com/inward/record.url?scp=85152025307&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85152025307&partnerID=8YFLogxK
U2 - 10.3390/vaccines11030658
DO - 10.3390/vaccines11030658
M3 - Review article
C2 - 36992242
AN - SCOPUS:85152025307
SN - 2076-393X
VL - 11
JO - Vaccines
JF - Vaccines
IS - 3
M1 - 658
ER -